NCT03496636 Autologous Ovarian Tissue Transplantation
| NCT ID | NCT03496636 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Female Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2021-03-01 |
| Primary Completion | 2030-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5 participants in total. It began in 2021-03-01 with a primary completion date of 2030-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO08050491). The objective of this study is to study the efficacy and safety of autologous tissue transplantation in patients diagnosed with primary ovarian insufficiency after chemotherapy and/or radiation treatments.
Eligibility Criteria
Inclusion Criteria: * Previously cryopreserved ovarian tissue * Ovarian insufficiency and/or candidate for pregnancy * Good health * Oncologist's clearance Exclusion Criteria: * Patients considered to be high risk for surgical complications * Women with contraindication for pregnancy if goal is to achieve pregnancy * Women positive for the BRCA mutations * Women with a history of leukemia, ovarian cancer or a cancer that likely involved ovaries at the time of ovarian tissue collection * Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent * Current pregnancy
Contact & Investigator
Kyle Orwig, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh/University of Pittsburgh Medical Center
Frequently Asked Questions
Who can join the NCT03496636 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Female Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03496636 currently recruiting?
Yes, NCT03496636 is actively recruiting participants. Contact the research team at fertilitypreservation@upmc.edu for enrollment information.
Where is the NCT03496636 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT03496636 clinical trial?
NCT03496636 is sponsored by University of Pittsburgh. The principal investigator is Kyle Orwig, PhD at University of Pittsburgh/University of Pittsburgh Medical Center. The trial plans to enroll 5 participants.